On January 14, 2019, it was announced that Ratos acquires remaining shares in TFS. This acquisition is a natural next step of the change in ownership structure that started two years ago, when TFS founder Daniel Spasic sold 60% of TFS to Ratos, to fund the strategic growth of TFS. This change in ownership, does not involve any operational changes, and with Ratos 100% ownership, TFS will continue to develop and provide tailored flexible and innovative solutions to our biopharmaceutical customers and partners worldwide.
Commenting on the Ratos Press Release, János Filakovský, CEO at TFS said: “This is business as usual for us. TFS will continue to work according to our strategic plan, transforming the company to enable further growth. This strategic investment will enable us to attract, retain and develop the best talent to support our growth”
For further information, please contact andrew.copestake [at] tfscro.com (Andrew Copestake), EVP Global Business Development and Chief Commercial Officer at TFS International.
Read the Ratos press release here.